Prognostic and predictive factors in the adjuvant treatment of breast cancer

被引：8

作者：

Fukutomi T. ^{[1
]}

机构：

[1] Breast Surgery Division, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, 5-1-1, Tsukiji

来源：

Breast Cancer | 2002年 / 9卷 / 2期

关键词：

Breast cancer; HER-2; Histological grade; Predictive factor; Prognostic factor;

D O I：

10.1007/BF02967572

中图分类号：

学科分类号：

摘要：

The selection of systemic adjuvant therapy should be based on the appropriate prognostic and predictive factors. The established prognostic factors currently used in cases of primary breast cancer include axillary lymph node involvement, histologic subtype, tumor size, nuclear or histologic grade, estrogen (ER) and progesterone receptor (PR) status and proliferative index. Adjuvant chemotherapy has had an impact on the management of node-positive breast cancer, while the St. Gallen recommendations were established for postoperative adjuvant therapy for node-negative breast cancer. However, there is some contention regarding the histological (or nuclear) grading systems among different pathologists. With regard to biological measurements, the most useful prognostic/predictive factors are hormone receptor status and HER-2 overexpression. ER and PR status can be used to establish the necessity of hormone therapy in the adjuvant setting. If the anti-HER-2 antibody and/or anfiangiogenic agents are introduced into the adjuvant setting in the near future, determination of these factors is also recommended.

引用

页码：95 / 99

页数：4

共 52 条

[21]

Rosen P.P., Saigo P.E., Braun D.W., Et al., Predictors of recurrence in Stage i (T1NOM0) breast carcinoma, Ann Surg, 193, pp. 15-25, (1981)

[22]

Parham D.M., Hagen N., Brown R.A., Simplified method of grading primary carcinomas of the breast, J Clin Patho, 145, pp. 517-520, (1992)

[23]

Cook D.L., Weaber D.L., Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast, Am J Clin Pathol, 104, pp. 17-22, (1995)

[24]

Meyer J.S., McDivitt R.W., Stone K.R., Practical breast carcinoma cell kinetics: Review and updata, Breast Cancer Research and Treatment, 4, 2, pp. 79-88, (1984)

[25]

Wenger C.R., Beardslee S., Owens M.A., Pounds G., Oldaker T., Vendely P., Pandian M.R., Harrington D., Clark G.M., McGuire W.L., DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients, Breast Cancer Research and Treatment, 28, 1, pp. 9-20, (1993)

[26]

Gerdes J., Lemke H., Baisch H., Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67, Journal of Immunology, 133, 4, pp. 1710-1715, (1984)

[27]

Sahin A.A., Ro J., Ro J.Y., Et al., Ki-67 immunostaining node-negative stage I/II breast carcinoma. Significant correlation with prognosis, Cancer, 68, pp. 549-557, (1991)

[28]

Pierga J.-Y., Leroyer A., Viehl P., Mosseri V., Chevillard S., Magdelenat H., Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer, Breast Cancer Research and Treatment, 37, 1, pp. 57-64, (1996)

[29]

Clark G.M., Prognostic and predictive factors for breast cancer, Breast Cancer, 2, pp. 79-89, (1995)

[30]

Tsuda H., Sakamaki C., Tsugane S., Fukutomi T., Hirohashi S., A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases, Breast Cancer Research and Treatment, 48, 1, pp. 21-32, (1998)

← 1 2 3 4 5 6 →